跳到正文
Yakov Pakhomov MD, PhD· @yakov_pakhomov · X·· 12 小时前评分60
正文 · 原文

@adamfeuerstein Fair point on the control arm: for macroscopic stage III, neoadjuvant IO is now the bar (NADINA/S1801). But resected IIB/C and microscopic stage III have no neoadjuvant option — that's where INTerpath-001 matters. OS and subgroups will decide. #ESMO26

热度 0 · 0 赞 · 0 回复 · 0 转发

来源:Yakov Pakhomov MD, PhD · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org